301684-75-3

Upstream product

• 301684-95-7 (2R)-3-cyclopentyl-2-({[(phenylmethyl)oxy]amino}methyl)propanoic acid 
• 2258-42-6 formyl acetic anhydride 
• 64-18-6 formic acid 
• 301685-10-9 (2R)-3-cyclopentyl-2-(hydroxymethyl)-N-[(phenylmethyl)oxy]propanamide 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 301685-11-0 (3R)-3-(cyclopentylmethyl)-1-[(phenylmethyl)oxy]-2-azetidinone 
• 104-97-2 cyclopentanepropanoyl chloride 
• 1152109-83-5 (4S)-3-((2R)-3-cyclopentyl-2-{[(phenylmethyl)oxy]methyl}propanoyl)-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 301685-08-5 (4S)-3-[(2R)-3-cyclopentyl-2-(hydroxymethyl)propanoyl]-4-(phenylmethyl)-1,3-oxazolidin-2-one 
• 301685-09-6 (2R)-3-cyclopentyl-2-(hydroxymethyl)propanoic acid 

Downstream Products

• 941300-08-9 {(2R)-2-(cyclopentylmethyl)-3-[(2S)-2-(1-methyl-1H-tetrazol-5-yl)-1-pyrrolidinyl]-3-oxopropyl}[(phenylmethyl)oxy]formamide 
• 940962-50-5 N-[({1-[(2R)-3-cyclopentyl-2-({formyl[(phenylmethyl)oxy]amino}methyl)propanoyl]-L-prolyl}amino)methyl]-2-pyridinecarboxamide 
• 1091682-12-0 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-(4-methyl-benzyl)-carbamic acid benzyl ester 
• 1091682-16-4 {1-{(S)-2-[(R)-3-(benzyloxyl-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethy-butyryl}-4-(4-fluoro-benzyl)-piperidin-4-yl}-carbamic acid benzyl ester 
• 1091682-19-7 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-furan-2-ylmethyl-carbamic acid benzyl ester 
• 1091682-22-2 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-(5-methoxy-4-oxo-4H-pyran-2-ylmethyl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1152109-84-6 (2R)-3-cyclopentyl-2-({formyl[(phenylmethyl)oxy]amino}methyl)propanoic acid diisopropylethylamine salt 
• 1152110-13-8 ((2R)-3-(2-(2-chloro-5-fluoro-6-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-yl)-4-pyrimidinyl)hydrazino)-2-cyclopentylmethyl-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-16-1 ((2R)-3-(2-(6-(1-azetidinyl)-5-fluoro-2-methyl-4-pyrimidinyl)hydrazino)-2-cyclopentylmethyl-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-22-9 ((2R)-2-cyclopentylmethyl-3-(2-(2-ethyl-5-fluoro-6-(4-methyl-1-piperazinyl)-4-pyrimidinyl)hydrazino)-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-45-6 ((2R)-2-cyclopentylmethyl-3-(2-(6-((3S)-3,4-dimethyl-1-piperazinyl)-5-fluoro-2-methyl-4-pyrimidinyl)hydrazino)-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-48-9 ((2R)-2-cyclopentylmethyl-3-(2-(6-((3R)-3,4-dimethyl-1-piperazinyl)-5-fluoro-2-methyl-4-pyrimidinyl)hydrazino)-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-53-6 ((2R)-2-cyclopentylmethyl-3-(2-(5-fluoro-2-methyl-6-((2-pyridinylmethyl)amino)-4-pyrimidinyl)hydrazino)-3-oxopropyl)(phenylmethoxy)forrmamide 
• 1152110-60-5 ((2R)-2-cyclopentylmethyl-3-(2-(6-((2S)-2,4-dimethyl-1-piperazinyl)-5-fluoro-2-methyl-4-pyrimidinyl)hydrazino)-3-oxopropyl)(phenylmethoxy)forrmamide 

Relevant academic research and scientific papers

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3- oxopropyl}hydroxyformamide compounds of Formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity and in treatment methods for bacterial infections

A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF

The present invention relates to the novel antibacterial compounds having potent antibacterial activity as inhibitors of peptide deformylase. This invention further relates to pharmaceutically acceptable salts thereof, to processes for their preparation, and to pharmaceutical compositions containing them as an active ingredient.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

PEPTIDE DEFORMYLASE INHIBITORS

Novel PDF inhibitors of formulas (I) and (II), pharmaceutical compositions thereof and methods for their use in the treatment of bacterial infections are described.

PEPTIDE DEFORMYLASE INHIBITORS

Novel PDF inhibitors of Formula (I), pharmaceutical compositions thereof and their use in treating bacterial infections are described.

ANTIBACTERIAL AGENTS

Selected compounds of formula (I) are antibacterial agents: formula (I) wherein R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl (C1-C6 alkyl)- or aryl (C1-C6 /SUB

Antimicrobial agents

Compounds of formula (I) are antibacterial agents: wherein Z represents a radical of formula —N(OH)CH(=O) or of formula —C(=O)NH(OH), and R1-R4 are as defined in the specification. A method for the treatment of bacterial or protozoal infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially or antiprotozoally effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.